Milestone pharmaceuticals submits response to the fda's crl for cardamyst (etripamil) nasal spray for psvt following type a meeting

Montreal and charlotte, n.c., june 16, 2025 (globe newswire) -- milestone® pharmaceuticals inc. (nasdaq: mist) today announced submission of its response to the u.s. food and drug administration (fda)'s complete response letter (crl) regarding its new drug application (nda) for cardamyst™ (etripamil) nasal spray, a prescription medication in development for the conversion of acute episodes of paroxysmal supraventricular tachycardia (psvt) to sinus rhythm in adults.
CRL Ratings Summary
CRL Quant Ranking